Cargando…

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells

Proteasome inhibition is an attractive approach for anticancer therapy. Doxorubicin (DOX) is widely used for treatment in a number of cancers including breast cancer; however, the development of DOX resistance largely limits its clinical application. One of the possible mechanisms of DOX-resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yonghua, Yu, Yang, Wang, Zhenyu, Wang, Hao, Bieerkehazhi, Shayahati, Zhao, Yanling, Suzuk, Lale, Zhang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342008/ https://www.ncbi.nlm.nih.gov/pubmed/27655642 http://dx.doi.org/10.18632/oncotarget.12048

Ejemplares similares

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016)

Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis
por: Wang, Hao, et al.
Publicado: (2016)

TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2017)

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
por: Efentakis, Panagiotis, et al.
Publicado: (2020)

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
por: Han, Bo, et al.
Publicado: (2015)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
por: Chen-Scarabelli, Carol, et al.
Publicado: (2017)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis
por: Wang, Mopei, et al.
Publicado: (2019)

Survivin Regulates Bad Gene Expression by Binding to Its Promoter and Modulates Cell Cycle and Apoptosis in Esophageal Carcinoma Cell
por: Chen, Yan, et al.
Publicado: (2021)

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
por: Lee, Min Jae, et al.
Publicado: (2019)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice
por: Park, Ji Eun, et al.
Publicado: (2017)

Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
por: Li, Haoyu, et al.
Publicado: (2016)

T cell receptor–dependent S-acylation of ZAP-70 controls activation of T cells
por: Tewari, Ritika, et al.
Publicado: (2021)

TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells
por: Wang, Zhenyu, et al.
Publicado: (2016)

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
por: Tundo, Grazia Raffaella, et al.
Publicado: (2022)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
por: Shen, Xuxing, et al.
Publicado: (2021)

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016)

Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome
por: Yago, Marc R., et al.
Publicado: (2023)

Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway
por: Guo, Kevin Y., et al.
Publicado: (2017)

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
por: Lee, Susan J., et al.
Publicado: (2016)

Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma
por: Wang, Xiaobin, et al.
Publicado: (2021)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani, Divaya, et al.
Publicado: (2017)

Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line
por: Hosseini, Maryam Sadat, et al.
Publicado: (2019)

Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells
por: XU, YE, et al.
Publicado: (2015)

Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology
por: Qin, Lei, et al.
Publicado: (2018)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy
por: Hsu, Chin-Mu, et al.
Publicado: (2022)

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
por: Allmeroth, Kira, et al.
Publicado: (2020)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
por: Turner, Joel G., et al.
Publicado: (2016)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer
por: Zulkifli, Ahmad, et al.
Publicado: (2021)

Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
por: Di Martile, Marta, et al.
Publicado: (2018)

Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo
por: Chen, Zhenghu, et al.
Publicado: (2017)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
por: Li, Jieqing
Publicado: (2023)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
por: Li, Qian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lc8pqar6vv66jp6j1mcdeg41e7